Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Subscribe To Our Newsletter & Stay Updated
